Previously, we showed that a lack of CD4+ T helper type 1 (Th1) cells in the tumor at baseline, and their inability to cluster with CD8+ T-cells and myeloid cells upon treatment, were associated with resistance to pembrolizumab (18). The gene discussed is CD4; the disease is neoplasm.